QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Forecast, Price & News

$1.47
+0.05 (+3.52%)
(As of 09/26/2023 ET)
Compare
Today's Range
$1.37
▼
$1.58
50-Day Range
$1.42
▼
$2.76
52-Week Range
$0.61
▼
$4.19
Volume
212,210 shs
Average Volume
539,958 shs
Market Capitalization
$71.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.63
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Corvus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
350.7% Upside
$6.63 Price Target
Short Interest
Healthy
3.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.57) to ($0.56) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

667th out of 964 stocks

Pharmaceutical Preparations Industry

299th out of 445 stocks

See Top Rated MarketRank™ Stocks Here

CRVS stock logo

About Corvus Pharmaceuticals (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

CRVS Price History

CRVS Stock News Headlines

September 12, 2023 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)
September 8, 2023 | fool.com
Corvus Pharmaceuticals (NASDAQ: CRVS)
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 7, 2023 | msn.com
Cantor Fitzgerald Reiterates Corvus Pharmaceuticals (CRVS) Overweight Recommendation
September 6, 2023 | finance.yahoo.com
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
August 18, 2023 | markets.businessinsider.com
Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer
August 8, 2023 | finance.yahoo.com
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
August 1, 2023 | msn.com
Circling Back On Corvus Pharmaceuticals
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 1, 2023 | finance.yahoo.com
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
July 6, 2023 | finance.yahoo.com
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
June 29, 2023 | finance.yahoo.com
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
June 29, 2023 | finance.yahoo.com
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
June 15, 2023 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Corvus Pharmaceuticals (CRVS)
June 15, 2023 | seekingalpha.com
Aldeyra, Bioventus top healthcare gainers; Mersana, Bone Biologics among losers
June 4, 2023 | finance.yahoo.com
Individual investors among Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) largest shareholders, saw gain in holdings value after stock jumped 23% last week
May 31, 2023 | finance.yahoo.com
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 30, 2023 | msn.com
Ladenburg Thalmann Maintains Corvus Pharmaceuticals (CRVS) Buy Recommendation
May 26, 2023 | finance.yahoo.com
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
May 17, 2023 | finance.yahoo.com
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
May 12, 2023 | seekingalpha.com
Corvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Market
May 12, 2023 | finance.yahoo.com
Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why
May 10, 2023 | finanznachrichten.de
Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
May 10, 2023 | benzinga.com
Why Are Corvus Pharmaceuticals Trading Higher Today
May 9, 2023 | msn.com
Cantor Fitzgerald Maintains Corvus Pharmaceuticals (CRVS) Overweight Recommendation
April 20, 2023 | finance.yahoo.com
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
April 17, 2023 | finance.yahoo.com
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
See More Headlines
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRVS
CUSIP
N/A
CIK
1626971
Web
www.corvuspharma.com
Phone
(650) 900-4520
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.63
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+324.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-41,310,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-71.23%
Return on Assets
-58.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.82
Quick Ratio
4.82

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.21 per share
Price / Book
1.29

Miscellaneous

Outstanding Shares
48,970,000
Free Float
33,640,000
Market Cap
$76.39 million
Optionable
Not Optionable
Beta
0.98
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Richard A. Miller M.D. (Age 72)
    Co-Founder, Pres, CEO & Chairman
    Comp: $306k
  • Dr. Peter A. Thompson FACP (Age 63)
    M.D., Co-Founder & Independent Director
    Comp: $47k
  • Mr. Leiv Lea (Age 69)
    Chief Financial Officer
    Comp: $388.73k
  • Dr. William Benton Jones Ph.D. (Age 57)
    Sr. VP of Pharmaceutical Devel.
    Comp: $346.42k
  • Dr. James T. Rosenbaum M.D.
    Sr. VP of Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CRVS Stock - Frequently Asked Questions

Should I buy or sell Corvus Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRVS shares.
View CRVS analyst ratings or view top-rated stocks.

What is Corvus Pharmaceuticals' stock price forecast for 2023?

4 equities research analysts have issued 1-year price objectives for Corvus Pharmaceuticals' stock. Their CRVS share price forecasts range from $3.50 to $12.00. On average, they expect the company's stock price to reach $6.63 in the next year. This suggests a possible upside of 324.7% from the stock's current price.
View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts.

How have CRVS shares performed in 2023?

Corvus Pharmaceuticals' stock was trading at $0.85 at the beginning of the year. Since then, CRVS shares have increased by 83.5% and is now trading at $1.56.
View the best growth stocks for 2023 here.

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,370,000 shares, an increase of 21.2% from the August 15th total of 1,130,000 shares. Based on an average daily trading volume, of 603,300 shares, the days-to-cover ratio is presently 2.3 days. Currently, 3.8% of the company's stock are sold short.
View Corvus Pharmaceuticals' Short Interest.

When is Corvus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CRVS earnings forecast.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14).

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.09%), Renaissance Technologies LLC (1.00%), Geode Capital Management LLC (0.70%), Marshall Wace LLP (0.61%), Towerview LLC (0.44%) and CHI Advisors LLC (0.41%). Insiders that own company stock include Ecor1 Capital, Llc, Leiv Lea, Linda Grais, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones.
View institutional ownership trends.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $1.56.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $76.39 million. The company earns $-41,310,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com.

This page (NASDAQ:CRVS) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -